Nivalis Therapeutics Inc. (NASDAQ:NVLS) shares rose 7.4% during mid-day trading on Monday . The stock traded as high as $5.48 and last traded at $5.40, with a volume of 56,575 shares. The stock had previously closed at $5.03.

NVLS has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Tuesday, July 12th. Cowen and Company reiterated a “buy” rating on shares of Nivalis Therapeutics in a report on Monday, May 2nd.

The stock has a 50-day moving average of $4.58 and a 200 day moving average of $4.58. The company’s market capitalization is $83.72 million.

Nivalis Therapeutics (NASDAQ:NVLS) last posted its quarterly earnings data on Monday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. Analysts predict that Nivalis Therapeutics Inc. will post ($2.28) EPS for the current fiscal year.

In other news, CMO David Malcom Rodman sold 5,950 shares of the firm’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $4.66, for a total transaction of $27,727.00. Following the sale, the chief marketing officer now owns 18,055 shares in the company, valued at approximately $84,136.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.